Benitec Biopharma (BNTC)
(Delayed Data from NSDQ)
$8.15 USD
-0.01 (-0.12%)
Updated Sep 13, 2024 03:59 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Benitec Biopharma Limited falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 19 | 18 | 14 | 9 |
Income After Depreciation & Amortization | 0 | -19 | -18 | -14 | -8 |
Non-Operating Income | NA | 0 | 0 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -20 | -18 | -14 | -8 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -20 | -18 | -14 | -8 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -20 | -18 | -14 | -8 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -19 | -18 | -13 | -8 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -19 | -18 | -14 | -8 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | 1.39 | 0.48 | 0.25 | 0.06 |
Diluted EPS Before Non-Recurring Items | NA | -14.12 | -37.93 | -54.93 | -137.76 |
Diluted Net EPS (GAAP) | NA | -14.12 | -37.93 | NA | -137.76 |
Fiscal Year end for Benitec Biopharma Limited falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.01 |
Cost Of Goods | NA | 0.00 | 0.00 | -0.11 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.11 | 0.01 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.15 | 6.92 | 5.98 | 4.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.15 | -6.92 | -5.87 | -4.55 |
Non-Operating Income | NA | -0.13 | 0.14 | -0.07 | -0.10 |
Interest Expense | NA | 0.00 | 0.01 | 0.01 | 0.01 |
Pretax Income | NA | -4.28 | -6.80 | -5.95 | -4.66 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.28 | -6.80 | -5.95 | -4.66 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.28 | -6.80 | -5.95 | -4.66 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 2.62 | 2.58 | 2.16 | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.64 | -2.64 | -2.76 | NA |
Diluted Net EPS (GAAP) | NA | -1.64 | -2.64 | -2.76 | 1,590.64 |